GL1X · GenesisL1 explorer

Research workbench

E. COLI phosphoenolpyruvate carboxykinase G209S K212C mutant bound to thiosulfate

Analyse E. COLI phosphoenolpyruvate carboxykinase G209S K212C mutant bound to… in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
6ASM
Type
protein
Length
527 residues
Chains
1
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Phosphoenolpyruvate carboxykinase (ATP)
EC
4.1.1.49
UniProt
P22259
Ligands
ATP, THJ, MG, MN, XE
Pockets
2 · best druggability 0.70

Structure

x-ray diffraction · 1 distinct chain · 31% helix, 25% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
APhosphoenolpyruvate carboxykinase (ATP) (EC 4.1.1.49)protein52731% helix, 25% strandP22259

Ligands and binding sites

  • ATP · Adenosine-5'-triphosphate · ligand · chains A
  • THJ · Thiosulfate · ligand · chains A
  • MG · Magnesium ion · metal · chains A
  • MN · Manganese (II) ion · metal · chains A
  • XE · Xenon · ion · chains A
  • BTB · 2-[bis-(2-hydroxy-ethyl)-amino]-2-hydroxymethyl-propane-1,3-diol · additive · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

2 pockets found on a 1 Å grid, 1 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
15810.700.7979ATP, MG, MN, THJ
21050.410.7619empty

Compared structures

  • 6ASM · E. coli phosphoenolpyruvate carboxykinase G209S K212C mutant bound to thiosulfate · the same entry in another collection · chain A against A, TM-score 1.00
  • P22259 · AlphaFold monomer V2.0 prediction for phosphoenolpyruvate carboxykinase (ATP) (P22259) · a predicted model of the same protein · chain A against A, TM-score 0.95

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.